Edwards Lifesciences Corp (EW) Insider Transactions
Over the last 12 months, 18 Edwards Lifesciences Corp (EW) insiders filed 190 SEC Form 4 transactions — $0 in open-market purchases ( 0 distinct buyers) and $25.2M in open-market sales. 11% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $25.2MOpen-market sells (1y)
- 18Distinct insiders
- 190Transactions filed
- 11%Under Rule 10b5-1 plan
- 2026-07-30Latest filing
Recent Form 4 Filings Most recent 50 of 190 (1-year window)
Each row is a single Form 4 filing event for EW, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-07-30 | Markowitz Wayne | CVP, JAPAC | Sell | S | $12.6K | 146 | $86.0 |
| 2026-07-28 | Markowitz Wayne | CVP, JAPAC | Exercise | M | $712.7K | 9,628 | $74.0 |
| 2026-07-28 | Markowitz Wayne | CVP, JAPAC | Exercise | M | $0 | 9,628 | $0.0 |
| 2026-07-28 | Markowitz Wayne | CVP, JAPAC | Sell | S | $819.0K | 9,628 | $85.1 |
| 2026-07-27 | Zovighian Bernard J | CEO | Other | G | $0 | 320 | $0.0 |
| 2026-07-27 | Zovighian Bernard J | CEO | Other | G | $0 | 320 | $0.0 |
| 2026-07-27 | Zovighian Bernard J | CEO | Sell | S | $245.1K | 2,921 | $83.9 |
| 2026-07-11 | Bruls Annette | CVP, EMEACLA | Other | F | $10.1K | 109 | $92.2 |
| 2026-07-10 | Lippis Daniel J. | CVP, TAVR | Exercise 10b5-1 | M | $45.0K | 619 | $72.7 |
| 2026-07-10 | Lippis Daniel J. | CVP, TAVR | Exercise | M | $0 | 619 | $0.0 |
| 2026-07-10 | Lippis Daniel J. | CVP, TAVR | Sell 10b5-1 | S | $56.8K | 619 | $91.7 |
| 2026-07-09 | Mistras Theodora | CVP, Chief Financial Officer | Grant | A | $0 | 87,595 | $0.0 |
| 2026-07-09 | Mistras Theodora | CVP, Chief Financial Officer | Grant | A | $0 | 12,325 | $0.0 |
| 2026-07-09 | Mistras Theodora | CVP, Chief Financial Officer | Grant | A | $0 | 61,800 | $0.0 |
| 2026-07-09 | Mistras Theodora | CVP, Chief Financial Officer | Grant | A | $0 | 12,325 | $0.0 |
| 2026-07-07 | Lippis Daniel J. | CVP, TAVR | Other | F | $35.9K | 377 | $95.2 |
| 2026-06-30 | Lippis Daniel J. | CVP, TAVR | Exercise 10b5-1 | M | $45.0K | 619 | $72.7 |
| 2026-06-30 | Lippis Daniel J. | CVP, TAVR | Exercise | M | $0 | 619 | $0.0 |
| 2026-06-30 | Lippis Daniel J. | CVP, TAVR | Sell 10b5-1 | S | $56.6K | 619 | $91.4 |
| 2026-06-17 | Zovighian Bernard J | CEO | Sell 10b5-1 | S | $46.0K | 523 | $87.9 |
| 2026-05-29 | Dahl Andrew M. | SVP, Corporate Controller | Sell | S | $48.9K | 568 | $86.1 |
| 2026-05-27 | BOBO DONALD E JR | CVP,Strategy/Corp Development | Sell | S | $2.0M | 23,145 | $86.4 |
| 2026-05-22 | Chopra Daveen | CVP, TMTT & Surgical | Sell | S | $126.9K | 1,500 | $84.6 |
| 2026-05-18 | Lippis Daniel J. | CVP, TAVR | Exercise 10b5-1 | M | $45.1K | 620 | $72.7 |
| 2026-05-18 | Lippis Daniel J. | CVP, TAVR | Exercise | M | $0 | 620 | $0.0 |
| 2026-05-18 | Lippis Daniel J. | CVP, TAVR | Sell 10b5-1 | S | $50.3K | 620 | $81.1 |
| 2026-05-15 | BOBO DONALD E JR | CVP,Strategy/Corp Development | Sell | S | $818.1K | 9,968 | $82.1 |
| 2026-05-15 | BOBO DONALD E JR | CVP,Strategy/Corp Development | Sell | S | $654.6K | 8,000 | $81.8 |
| 2026-05-12 | Zovighian Bernard J | CEO | Other | G | $0 | 26,640 | $0.0 |
| 2026-05-12 | Zovighian Bernard J | CEO | Other | G | $0 | 26,640 | $0.0 |
| 2026-05-12 | Zovighian Bernard J | CEO | Sell 10b5-1 | S | $66.3K | 845 | $78.4 |
| 2026-05-12 | Zovighian Bernard J | CEO | Sell 10b5-1 | S | $2.8M | 35,506 | $77.9 |
| 2026-05-11 | Ullem Scott B. | CVP, Chief Financial Officer | Exercise | M | $0 | 19,830 | $0.0 |
| 2026-05-11 | Ullem Scott B. | CVP, Chief Financial Officer | Exercise | M | $0 | 19,830 | $0.0 |
| 2026-05-11 | Zovighian Bernard J | CEO | Exercise | M | $0 | 47,207 | $0.0 |
| 2026-05-11 | Zovighian Bernard J | CEO | Exercise | M | $0 | 47,207 | $0.0 |
| 2026-05-11 | BOBO DONALD E JR | CVP,Strategy/Corp Development | Exercise | M | $0 | 13,457 | $0.0 |
| 2026-05-11 | BOBO DONALD E JR | CVP,Strategy/Corp Development | Exercise | M | $0 | 13,457 | $0.0 |
| 2026-05-11 | Chopra Daveen | CVP, TMTT & Surgical | Exercise | M | $0 | 13,583 | $0.0 |
| 2026-05-11 | Chopra Daveen | CVP, TMTT & Surgical | Exercise | M | $0 | 13,583 | $0.0 |
| 2026-05-11 | Ullem Scott B. | CVP, Chief Financial Officer | Other | F | $879.9K | 11,004 | $80.0 |
| 2026-05-11 | Zovighian Bernard J | CEO | Other | G | $0 | 5,489 | $0.0 |
| 2026-05-11 | Zovighian Bernard J | CEO | Other | G | $0 | 5,489 | $0.0 |
| 2026-05-11 | Lippis Daniel J. | CVP, TAVR | Other | F | $28.9K | 362 | $80.0 |
| 2026-05-11 | Zovighian Bernard J | CEO | Other | F | $2.1M | 26,198 | $80.0 |
| 2026-05-11 | BOBO DONALD E JR | CVP,Strategy/Corp Development | Other | F | $597.2K | 7,469 | $80.0 |
| 2026-05-11 | Chopra Daveen | CVP, TMTT & Surgical | Other | F | $602.7K | 7,538 | $80.0 |
| 2026-05-11 | Markowitz Wayne | CVP, JAPAC | Sell | S | $47.3K | 593 | $79.7 |
| 2026-05-08 | VALERIANI NICHOLAS J | — | Grant | A | $0 | 5,127 | $0.0 |
| 2026-05-08 | Sequeira Ramona | — | Grant | A | $0 | 3,251 | $0.0 |
Showing the most recent 50 of 190 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Methodology & FAQ
How We Track EW Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for Edwards Lifesciences Corp?
Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of Edwards Lifesciences Corp (EW) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of Edwards Lifesciences Corp (EW) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.